Related Experiment Videos
Eptifibatide-induced profound thrombocytopenia
N Gupta1, R Kapoor, S Bhandari
1Department of Invasive Cardiology, Escorts Heart Institute and Research Centre, New Delhi.
Indian Heart Journal
|December 9, 2004
Summary
Eptifibatide therapy can cause severe thrombocytopenia, a condition of low platelet count. This adverse effect resolved rapidly after discontinuing the drug.
Area of Science:
- Cardiology
- Pharmacology
- Hematology
Background:
- Eptifibatide is an antiplatelet medication used to prevent blood clots.
- Thrombocytopenia is a known potential side effect of certain antiplatelet agents.
- Understanding the temporal relationship between drug administration and adverse events is crucial for patient safety.
Observation:
- A patient developed profound thrombocytopenia (critically low platelet count) approximately 2 hours after initiating eptifibatide treatment.
- The thrombocytopenia was severe, indicating a significant risk to the patient.
Findings:
- The patient's platelet count returned to normal levels within 12 hours of discontinuing eptifibatide.
- This rapid reversal strongly suggests a direct causal link between eptifibatide and the observed thrombocytopenia.
Implications:
- Clinicians should be vigilant for thrombocytopenia in patients receiving eptifibatide.
- Prompt discontinuation of eptifibatide may be necessary to manage this adverse event.
- This case highlights the importance of monitoring platelet counts during eptifibatide therapy.